IPR loss widens 40% to NZ$164.7m as NZ$2.1bn cash is deployed into impairing...

What changed

• Revenue, which is solely interest income, fell 55.4% to NZ$11.3m (FY21: NZ$25.3m), directly reflecting the collapse in the cash balance from NZ$2.1b to NZ$21.7m.
• The statutory loss widened 40% to NZ$164.7m (FY21 loss: NZ$117.6m). Because no tax was recognised in either year, PBT and NPAT are identical and there is no tax distortion to strip out.
• Operating cash outflow narrowed marginally to NZ$119.1m from NZ$123.6m.
• The balance-sheet shape changed materially: total assets fell only NZ$119.2m (-5.5%) despite cash falling NZ$2.1bn, implying roughly NZ$2.0bn was redeployed into non-cash assets. Total liabilities rose 54.5% to NZ$128.9m and equity declined by NZ$164.7m, matching the loss (no other equity movements).
• No dividend was declared, consistent with the prior year.

What matters

• The cash has been invested, and the investment is losing money. With interest-earning cash largely gone, the P&L now reflects the performance of whatever the NZ$2.0bn was deployed into. That this produced a larger loss than FY21's pre-deployment year is the most important signal in this release.
• Earnings are effectively driven by non-operating movements. Revenue of NZ$11.3m cannot explain a NZ$164.7m loss; the gap is consistent with fair-value or impairment-style charges on the newly-held assets, though the supplied excerpts do not itemise them.
• Liquidity runway has reset. Closing cash of NZ$21.7m against an annual operating cash outflow of NZ$119.1m means the vehicle no longer has the self-funding capacity it had a year ago; liabilities up 54.5% compound that shift. Stated strategy remains the pursuit of acquisition targets "with the support of the majority".

Expectations

No quantitative targets, forward-work disclosures, or guidance were provided, so there is no benchmark against which to measure this result. The only shape context is HY22, where H1 produced 35.7% of full-year revenue and 65.2% of the full-year loss; by implication H2 revenue of ~NZ$7.2m was higher than H1's NZ$4.0m, and the H2 loss of ~NZ$57.3m was smaller than H1's NZ$107.4m. That pattern is directionally less bad in the second half, but given the result is dominated by investment carrying values rather than trading operations, period-to-period shape is of limited predictive use.

Quality of result

The result is low quality for read-across purposes. Statutory revenue is a passive interest return on cash rather than operating revenue, and the NZ$164.7m loss is far larger than anything revenue can explain, so the bulk of the print is a balance-sheet revaluation outcome rather than a recurring operating earnings stream. Operating cash outflow of NZ$119.1m is only modestly better year on year and remains well above revenue, confirming that the underlying cost base is not covered by earned income. Capex, free cash flow, gross borrowings, and net debt are not disclosed, so cash conversion and leverage cannot be assessed directly.

Unresolved

• What specific assets absorbed the ~NZ$2.0bn cash deployment, and what proportion of the NZ$164.7m loss is fair-value/impairment versus operating cost?
• What drove the 54.5% jump in total liabilities to NZ$128.9m, and is any portion interest-bearing debt?
• With closing cash of only NZ$21.7m against a ~NZ$119m annual operating cash burn, what is the funding plan — and how does this interact with the stated search for acquisition targets?
• Is the "majority" referenced in the outlook a controlling shareholder whose consent is required, and does that constrain strategic flexibility?

This briefing cannot assess the nature, valuation basis, or recoverability of the assets that replaced the cash balance, because the underlying holdings and any fair-value movements are not disclosed in the supplied extraction.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.